




Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



ORIGINAL ARTICLE

Nine compounds from the root bark of *Lycium chinense* and their anti-inflammatory activities



Yanan Yang^{a,†}, Yawen An^{a,†}, Wei Wang^b, Ning Du^b, Jinghua Zhang^b,
Ziming Feng^a, Jianshuang Jiang^a, Peicheng Zhang^{a,*}

^aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

^bBeijing Centre for Physical and Chemical Analysis, Beijing 100089, China

Received 19 February 2017; received in revised form 2 March 2017; accepted 3 March 2017

KEY WORDS

Lycium chinense;
Lyciumlignan D;
Lyciumphenyl propanoid A;
Structure elucidation;
Anti-inflammatory effect

Abstract Two new compounds, named lyciumlignan D (**1**) and lyciumphenyl propanoid A (**2**), along with seven known compounds, were isolated from the root bark of *Lycium chinense*. Their structures were elucidated using spectroscopic data (UV, IR, HR-ESI-MS, 1D and 2D NMR, CD), as well as by comparison with those of the literature. Compounds **3–9** were isolated from this genus for the first time. In the *in vitro* assay, compounds **3**, **6**, and **7** exhibited stronger anti-inflammatory effects than the positive control curcumin at a concentration of 10 μmol/L.

© 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Corresponding author.

E-mail address: pczhang@imm.ac.cn (Peicheng Zhang).

[†]These authors made equal contributions to this work.

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

1. Introduction

The root bark of *Lycium chinense* Mill. or *Lycium barbarum* L., named Digupi in China, is a famous traditional Chinese medicine. During the recent decades, it has been used for treating diabetes, cough, hypertension, and fever. Previous phytochemical investigations have been reported for different types of chemical constituents, including alkaloids, cyclopeptides, lignans, anthraquinones, coumarines, flavonoids, terpenoids, sterols, and other compounds^{1–13}. As part of an ongoing effort for bioactive constituents from the root bark of *L. chinense*, two new compounds (lyciumlignan D and lyciumpheyl propanoid A, Fig. 1) and seven known compounds (**3–9**) were isolated. In addition, all of the isolates were tested for anti-inflammatory activity by suppressing the production of NO in lipopolysaccharide-induced BV2 cells. In this paper, we reported the isolation, structure elucidation, and bioactivity evaluation of the compounds isolated from the root bark of *L. chinense*.

2. Results and discussion

Compound **1** was obtained as a white amorphous powder, whose molecular formula was confirmed to be C₂₇H₃₆O₁₄ by the sodiated molecular ion peak observed at *m/z* 607.2000 [M + Na]⁺ in the HR-ESI-MS. In the IR spectrum, absorption bands for hydroxyl group (3382 cm⁻¹), chemical bond –CH₂– (2929 cm⁻¹), and aromatic ring (1616, 1518, and 1463 cm⁻¹) were observed. The ¹H NMR spectrum (Table 1) displayed four aromatic proton signals at δ_H 6.63 (2 H, s), 6.87 (1 H, d, *J* = 1.5 Hz), and 6.86 (1 H, d, *J* = 1.5 Hz), revealing the presence of two tetra-substituted aromatic rings. In the upfield region, four oxymethylene protons at δ_H 3.67 (1 H, m), 3.60 (1 H, m), 3.35 (1 H, m), and 3.16 (1 H, m), three oxymethine protons at δ_H 5.39 (1 H, d, *J* = 7.0 Hz), 4.55

(1 H, d, *J* = 6.0 Hz), and 3.63 (1 H, m), and one methine proton at δ_H 3.46 (1 H, m) were detected. In addition, three methoxyl groups at δ_H 3.72 (6 H, s) and 3.76 (3 H, s) and a glucopyranosyl anomeric proton at δ_H 4.39 (1 H, d, *J* = 7.5 Hz) were observed. The ¹³C NMR spectrum (Table 1) of **1** exhibited 27 carbon signals, apart from three methoxyl groups and six carbon signals of one *O*-glucose unit, and the remaining 18 carbon signals could be attributed to a lignan skeleton^{4,14}. The HMBC correlations (Fig. 2) from H-7 (δ_H 5.39) to C-1, C-2, C-6, C-8, and C-9, and from H-7' (δ_H 4.55) to C-1', C-2', C-6', C-8' and C-9' confirmed the presence of two C6-C3 units. Furthermore, the key correlations from H-8 (δ_H 3.46) to C-4', C-5', and C-6', and from H-7 (δ_H 4.55) to C-4' and C-5' verified that **1** was a benzofuran-type lignan. The locations of three methoxyl groups were determined to be at C-3, C-5, and C-3' by the HMBC correlations of δ_H 3.72, 3.72, 3.76 with C-3, C-5, C-3', respectively. Based on the HMBC correlation of the anomeric proton H-1'' correlated with C-7', the glucose unit was determined to be located at C-7'. The *trans* configuration between H-7 and H-8 was identified by a big coupling constant (*J*_{7,8} = 7.0 Hz). In combination with positive Cotton effect at 243 and 286 nm, the 7*S*,8*R* configurations of **1** was established¹⁴. Furthermore, the 7',8'-*threo* configuration was confirmed by the coupling constant of H-7' (*J*_{7,8} = 6.0 Hz). Unfortunately, the absolute configurations of C-7' and C-8' were not identified. From the above analysis, the structure of **1** was elucidated as shown, and was accorded the trivial name lyciumlignan D.

Compound **2** was isolated as a white amorphous powder. Its molecular formula (C₂₄H₃₆O₁₄) was deduced from positive HR-ESI-MS (*m/z* 571.2007 [M + Na]⁺). The IR spectrum similarly revealed the existence of hydroxyl, –CH₂–, and aromatic ring. In the ¹H NMR spectrum (Table 1), a set of ABX spin-system aromatic protons at δ_H 7.03 (1 H, d, *J* = 1.5 Hz), 7.00 (1 H, d, *J* = 8.0 Hz), and 6.88 (1 H, dd, *J* = 1.5, 8.0 Hz), a set of typical *trans*- double bond resonances at δ_H 6.45 (1 H, d, *J* = 16.0 Hz) and




Figure 1 Structures of compounds 1–9.

Table 1 ^1H NMR (500 MHz) and ^{13}C NMR (125 MHz) spectral data of compounds **1** and **2** in $\text{DMSO-}d_6$ (δ in ppm, J in Hz).

Position	1		2	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}
1		131.3		130.6
2	6.63, s	103.7	7.03, d (1.5)	109.9
3		147.9		149.8
4		135.3		146.6
5		147.9	7.00, d (8.0)	115.8
6	6.63, s	103.7	6.88, dd (1.5, 8.0)	119
7	5.39, d (7.0)	87.3	6.45, d (16.0)	128.5
8	3.46, m	53	6.25, dt (16.0, 5.0)	128.8
9	3.67, m	62.7	4.08, brd (5.0)	61.6
	3.60, m			
10			3.84, m	68
			3.68, m	
11			4.34, m	78.8
12			3.58, m	60
1'		133.5	4.19, d (8.0)	103.3
2'	6.87, d (1.5)	115.7	2.95, t (8.5)	73.3
3'		142.9	3.13, m	76.6
4'		146.6	3.00, t (9.0)	70
5'		128.7	3.24, m	75.4
6'	6.86, d (1.5)	112.2	3.41, m	67.5
7'	4.55, d (6.0)	82		
8'	3.63, m	75.2		
9'	3.35, m	61.9		
	3.16, m			
1''	4.39, d (7.5)	104.2	4.83, d (2.5)	109.2
2''	3.06, m	74.2	3.75, m	75.8
3''	3.02, m	76.9		78.8
4''	3.04, m	69.9	3.56, m	73.3
			3.76, m	
5''	3.14, m	76.4	3.32, m	63.2
6''	3.57, m	61		
	3.33, m			
3-CH ₃ O	3.72 (s)	56	3.76, s	55.5
5-CH ₃ O	3.72 (s)	56		
3''-CH ₃ O	3.76 (s)	55.7		

6.25 (1 H, dt, $J=16.0, 5.0$ Hz), two oxymethylene protons at δ_{H} 4.08 (2 H, brd, $J=5.0$ Hz), and a methoxy group at δ_{H} 3.76 (3 H, s) were displayed, which indicated the presence of a coniferyl alcohol unit. Additionally, four oxymethylene protons at δ_{H} 3.84 (1 H, m), 3.68 (1 H, m), and 3.58 (2 H, m), together with an oxymethine proton at δ_{H} 4.34 (1 H, m) confirmed the existence of a glycerol moiety. Two anomeric protons at δ_{H} 4.19 (1 H, d,

$J=8.0$ Hz) and 4.83 (1 H, d, $J=2.5$ Hz) were also observed in the upfield region, which could be assigned to a glucose moiety and an apiose moiety⁴. The ^{13}C NMR spectrum (Table 1) of **2** exhibited 24 carbon signals, including a coniferyl alcohol moiety, a glycerol moiety, a glucose moiety, and an apiose moiety. The connections between these moieties were established by the HMBC correlation peaks (Fig. 2). An obvious HMBC correlation from H-11 (δ_{H} 4.34) to C-4 (δ_{C} 146.6) indicating the C₁₁-O-C₄ connection between coniferyl alcohol and glycerol moiety. Moreover, the HMBC correlation of H-1' (δ_{H} 4.19) with C-10 (δ_{C} 68.0) revealed that the glucopyranose unit was attached to C-10, while the correlation of H-1'' (δ_{H} 4.83) with C-6' (δ_{C} 67.5) suggested that the apiofuranose unit was attached to C-6'. Consequently, the structure of **2** was identified as shown, and was accorded the trivial name lyciumphenylpropanoid A.


The structures of seven known compounds (**3–9**) isolated from the root bark of *L. chinense*, were also identified by comparison of their spectroscopic data to those found in the literature. They were elucidated as: periplocoside M (**3**)¹⁵, intrapilosin I (**4**)¹⁶, (–)-lyoniresinol-4,9'-di- O - β -D-glucopyranoside (**5**)¹⁷, cedrusin (**6**)¹⁸, smiglabrol (**7**)¹⁹, 2',5-dihydroxy-6,7,8,6'-tetramethoxy flavone (**8**)²⁰ and lycifuranone A (**9**)²¹.

All of the compounds were tested for their anti-inflammatory activities by suppressing the production of NO in lipopolysaccharide-induced BV2 cells. As a result, compounds **3**, **6**, and **7** exhibited 87.5%, 83.6%, and 75.0% inhibition at 10 $\mu\text{mol/L}$, respectively, whereas the positive control curcumin showed 65.75% inhibition at 10 $\mu\text{mol/L}$. Then, a further test of compounds **3**, **6**, and **7** was performed at 1 $\mu\text{mol/L}$, which demonstrated 60.0%, 56.9%, and 60.0% inhibition, respectively,

3. Experimental

3.1. General experimental procedure

Optical rotations were measured on a Jasco P-2000 polarimeter (Jasco Corp; Tokyo, Japan). The UV spectra were measured on a Jasco V650 spectrophotometer (Jasco). The IR spectra were recorded on a Nicolet 5700 spectrometer (Thermo Scientific, FL). The CD spectra were measured on a Jasco J-815 CD spectrometer (Jasco). High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) was performed on an Agilent 6520 HPLC-Q-TOF (Agilent Technologies, Waldbronn, Germany). ^1H NMR (500 MHz), ^{13}C NMR (125 MHz), and 2D NMR spectra were recorded with a Bruker 500 MHz spectrometer (Bruker-Biospin, Billerica, MA, USA) and values were given in ppm (δ). Column chromatography was carried out with macroporous resin (Diaion HP-20 and SP-700, Mitsubishi Chemical Corp, Tokyo,

**Figure 2** Key HMBC (H→C) correlations of compounds **1** and **2**.

Japan) and Sephadex LH-20 (Pharmacia Fine Chemicals, Uppsala, Sweden). Flash chromatography was conducted using Combiflash RF200 (Teledyne Isco Corp, Nebraska, USA). Preparative HPLC was carried out on a Shimadzu LC-10A instrument with a SPD-20A detector (Shimadzu Corp, Tokyo, Japan), using YMC-Pack ODS-A column (250 mm × 20 mm, 5 μm, YMC Corp, Kyoto, Japan). HPLC-DAD analysis was set up on Agilent 1200 series system (Agilent Technologies) with an Apollo C18 column (250 mm × 4.6 mm, 5 μm, Alltech Corp, Kentucky, USA).

3.2. Plant material

The root bark of the *L. chinense* was collected from Ningnan Town, Zhongning County, Ningxia Hui autonomous region, People's Republic of China, in March 2012. A voucher specimen (ID-S-2592) was deposited in the Herbarium of the Institute of Materia Medica, Chinese Academy of Medical Science, Beijing.

3.3. Extraction and isolation

The powdered plant material (100 kg) was extracted three times with 80% EtOH (600 L) under reflux. The solvent was evaporated and the crude residue (8.0 kg) was partitioned with EtOAc (3 × 45 L). The EtOAc and H₂O solvent were removed under reduced pressure, which yielded Fr. 1 and Fr. 2, respectively. Fr. 1 (1.5 kg) was subjected to column chromatography on silica gel and continuously eluted with petroleum ether, EtOAc, acetone, and methanol, which gave fractions I–IV. Fraction II was further separated on silica gel chromatography column, and eluted with petroleum ether–EtOAc (from 100:0 to 0:100) in a gradient to afford 10 fractions (fractions II-1–II-10). Fr. II-2 was chromatographed over Sephadex LH-20 and eluted with gradient mixtures of MeOH–H₂O (from 60:40 to 100:0) to yield Fr. II-2-1–II-2-16. Fr. II-2-5 was further purified with pHPLC (MeOH–H₂O, 65:35) to yield **8** (9 mg). Fr. II-6 was subjected to Combiflash RF200 apparatus with a C18 column (55 cm × 8 cm, 50 μm) and eluted with MeOH–H₂O (from 5:95 to 100:0) to provide Fr. II-6-1–Fr. II-6-20. Compound **3** (20 mg) was obtained from Fr. II-6-12 by recrystallization. Fr. II-8 was purified using reversed-phase preparative HPLC with MeOH–H₂O (60:40) as the mobile phase to give **4** (19 mg, min).

Fr. 2 (1.375 kg) was chromatographed with a macroporous resin column (HP-20, 200 cm × 15 cm) and eluted successively with H₂O, 15%, 30%, 50%, 70%, and 95% EtOH. The 30% EtOH fraction was concentrated and was further chromatographed over a macroporous resin (SP-700, 200 cm × 15 cm) and eluted successively with 15%, 20%, 25%, 30%, 45%, 50%, and 95% EtOH, which yielded fractions A–G. Fr. C (72 g) was subjected to Combiflash RF200 apparatus with a C18 column (55 cm × 8 cm, 50 μm) and eluted with MeOH–H₂O (from 5:95 to 100:0) to provide Fr. C1–Fr. C25. Fr. C2 (4 g) was chromatographed over Sephadex LH-20 and eluted with gradient mixtures of MeOH–H₂O (from 10:90 to 95:5) to yield Fr. C2-1–C2-19. Fr. C2-6 was purified with reverse-phase preparative HPLC (MeOH–H₂O, 30:70) to yield **1** (20 mg) and **2** (35 mg). Fr. C6 was separated on Sephadex LH-20 column (H₂O) and then further purified by reverse-phase preparative HPLC with MeOH–H₂O (40:60) to afford **5** (13 mg), **6** (8 mg), and **7** (6 mg). Similar to Fr. C6, compound **9** (20 mg) was isolated from Fr. C8.

3.3.1. Lyciumlignan D (I)

White amorphous powder, $[\alpha]_D^{20} + 22.9$ (c 0.10 MeOH); UV (MeOH) λ_{\max} (log ϵ): 238 (4.02), 282 (3.53) nm; CD (MeOH) λ_{\max}

($\Delta\epsilon$): 217 (+5.03), 242 (+4.14), 286 (+0.89) nm; IR (KBr) ν_{\max} : 3382, 2929, 2881, 1616, 1518, 1463, 1332, 1217, 1114, 1068 cm⁻¹; HR-ESI-MS: m/z 607.2000 [M+Na]⁺ (Calcd. for C₂₇H₃₆O₄Na, 607.1997); For ¹H NMR and ¹³C NMR spectroscopic data, see Table 1.

3.3.2. Lyciumphenylpropanoid A (2)

White amorphous powder, IR (KBr) ν_{\max} : 3354, 2934, 1576, 1511, 1420, 1266, 1229, 1048, 859, 778 cm⁻¹. HR-ESI-MS: m/z 571.2007 [M+Na]⁺ (Calcd. for C₂₄H₃₆O₁₄Na, 571.1997). For ¹H NMR and ¹³C NMR spectroscopic data, see Table 1.

3.4. Determination of the absolute configuration of sugar

Compounds **1** and **2** (2 mg) were separately dissolved in 1 mol/L CF₃COOH–H₂O (5 mL) and refluxed for 6 h. The mixture was concentrated under vacuum, and the residue was suspended in H₂O and extracted three times with EtOAc. The aqueous layer was evaporated under vacuum, diluted repeatedly with H₂O and evaporated under vacuum to produce a neutral residue. The residue was dissolved in fresh anhydrous pyridine (1.0 mL). L-Cysteine methyl ester hydrochloride (2 mg) was added, and the reaction mixture was incubated at 60 °C for 2 h. After that, *N*-trimethylsilylimidazole (0.2 mL) was added into the mixture which had been dried by nitrogen current. The reaction mixture was incubated at 60 °C for 2 h and partitioned between *n*-hexane and H₂O (2 mL each). The *n*-hexane extract was subjected to GC analysis under the following conditions: capillary column, HP-5 (60 m × 0.25 mm, with a 0.25 μm film, Dikma); Detection, FID; detector temperature, 300 °C; injection temperature, 300 °C; initial temperature 200 °C, then raised to 260 °C at 10 °C/min, final temperature maintained for 30 min; carrier, N₂ gas. The D-apiose and D-glucose were confirmed by comparing the retention time of their derivatives to the standard sugar derivatized, which exhibited retention times of 18 and 29 min, respectively.

3.5. Anti-inflammatory effects of compounds

Compounds **1–9** were tested for anti-inflammatory activity on BV2 microglial cells, using the same method as described in the Refs. 22 and 23.

Acknowledgements

This research was financially supported by the National Natural Science Foundation of China (No. 81303207) and CAMS Innovation Fund for Medical Sciences (CIFMS, No. 2016-I2M-1-007).

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.apsb.2017.04.004>.

References

- Li XN, Chu C, Tong SQ, Cheng DP, Yan JZ. A new furo lactone-type lignan from *Lycium chinense*. *Nat Prod Res* 2013;**27**:750–2.
- Pan S, Hou AJ. New long-chain hydroxyalkyl ferulates from the root bark of *Lycium chinense* Mill. *J Asian Nat Prod Res* 2009;**11**:681–5.

3. An YW, Zhan ZL, Xie J, Yang YN, Jiang JS, Feng ZM, et al. Bioactive octahydroxylated C21 steroids from the root bark of *Lycium chinense*. *J Nat Prod* 2016;**79**:1024–34.
4. Yang YN, An YW, Zhan ZL, Xie J, Jiang JS, Feng ZM, et al. Nine new compounds from the root bark of *Lycium chinense* and their α -glucosidase inhibitory activity. *RSC Adv* 2017;**7**:805–12.
5. Funayama S, Zhang GR, Nozoe S. Kukoamine B, a spermine alkaloid from *Lycium chinense*. *Phytochemistry* 1995;**38**:1529–31.
6. Liu X, Zheng X, Long Y, Cao H, Wang N, Lu Y, et al. Dual targets guided screening and isolation of kukoamine B as a novel natural anti-sepsis agent from traditional Chinese herb Cortex lycii. *Int Immunopharmacol* 2011;**11**:110–20.
7. Han SH, Lee HH, Lee IS, Moon YH, Woo ER. A new phenolic amide from *Lycium chinense* miller. *Arch Pharm Res* 2002;**25**:433–7.
8. Asano N, Kato A, Miyauchi M, Kizu H, Tomimori T, Matsui K, et al. Specific α -galactosidase inhibitors, *N*-methylcalystegines structure/activity relationships of calystegines from *Lycium chinense*. *Eur J Biochem* 1997;**248**:296–303.
9. Zhang JX, Guan SH, Feng RH, Wang Y, Wu ZY, Zhang YB, et al. Neolignanamides, lignanamides, and other phenolic compounds from the root bark of *Lycium chinense*. *J Nat Prod* 2013;**76**:51–8.
10. Yahara S, Shigeyama C, Ura T, Wakamatsu K, Yasuhara T, Nohara T. Cyclic peptides, acyclic diterpene glycosides and other compounds from *Lycium chinense* MILL. *Chem Pharm Bull* 1993;**41**:703–9.
11. Lee DG, Jung HJ, Woo ER. Antimicrobial property of (+)-lyonir- esinol-3 α -*O*- β -*D*-glucopyranoside isolated from the root bark of *Lycium chinense* Miller against human pathogenic microorganisms. *Arch Pharm Res* 2005;**28**:1031–6.
12. Lee DG, Park Y, Kim MR, Jung HJ, Seu YB, Hahm KS, et al. Anti-fungal effects of phenolic amides isolated from the root bark of *Lycium chinense*. *Biotechnol Lett* 2004;**26**:1125–30.
13. Zhang JX, Guan SH, Yang M, Feng RH, Wang Y, Zhang YB, et al. Simultaneous determination of 24 constituents in Cortex Lycii using high-performance liquid chromatography–triple quadrupole mass spectrometry. *J Pharm Biomed Anal* 2013;**77**:63–70.
14. Huang XY, Feng ZM, Yang YN, Jiang JS, Zhang PC. Four new neolignan glucosides from the fruits of *Arctium lappa*. *J Asian Nat Prod Res* 2015;**17**:504–11.
15. Itokawa H, Xu JP, Takeya K. Studies on chemical constituents of antitumor fraction from *Periploca sepium*. IV.: structures of new pregnane glycosides, periplocosides D, E, L, and M. *Chem Pharm Bull* 1988;**36**:2084–9.
16. Bah M, Chérigo L, Taketa AT, Fragoso-Serrano M, Hammond GB, Pereda-Miranda R. Intrapilosins I–VII, pentasaccharides from the seeds of *Ipomoea intrapilosa*. *J Nat Prod* 2007;**70**:1153–7.
17. Sun J, Yu J, Zhang PC, Tang F, Yue YD, Yang YN, et al. Isolation and identification of lignans from Caulis Bambusae in Taenia with antioxidant properties. *J Agric Food Chem* 2013;**61**:4556–62.
18. Pieters L, de Bruyne T, Claeys M, Vlietinck A, Calomme M, vanden Berghe D. Isolation of a dihydrobenzofuran lignan from south American dragon's blood (*Croton* spp.) as an inhibitor of cell proliferation. *J Nat Prod* 1993;**56**:899–906.
19. Xu S, Shang MY, Liu GX, Xu F, Wang X, Shou CC, et al. Chemical constituents from the rhizomes of *Smilax glabra* and their antimicrobial activity. *Molecules* 2013;**18**:5265–87.
20. Tsai PJ, Huang WC, Hsieh MC, Sung PJ, Kuo YH, Wu WH. Flavones isolated from *Scutellariae radix* suppress propionibacterium acnes-induced cytokine production *in vitro* and *in vivo*. *Molecules* 2015;**21**:E15.
21. Guo F, Li Y. New sesquiterpenoids from *Lycianthes marlipoensis*. *Helv Chim Acta* 2005;**88**:2364–9.
22. Yang YN, Huang XY, Feng ZM, Jiang JS, Zhang PC. New butyrolactone type lignans from *Arctii Fructus* and their anti-inflammatory activities. *J Agric Food Chem* 2015;**63**:7958–66.
23. Xu K, Jiang JS, Feng ZM, Yang YN, Li L, Zang CX, et al. Bioactive sesquiterpenoid and polyacetylene glycosides from *Atractylodes lancea*. *J Nat Prod* 2016;**79**:1567–75.